Belatacept and carfilzomib-based treatment for antibody-mediated rejection in a sensitized nonhuman primate kidney transplantation model.

Front Transplant · 2023 · PMC11235304 · PMID 38993898

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, in animals receiving AMR treatment, T cell flow crossmatch (TFCM) showed a significant reduction of DSA after initiation of treatment while B cell flow crossmatch showed a trend towards reduced DSA titers ( Figure 2A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.